The clinical research network announced that it has fast-tracked updates to its real-world data (RWD) platform in order to better support the industry during the coronavirus epidemic.
The updates include incorporation of specific COVID-19 terminology based on the guidelines provided by the World Health Organization (WHO) and Centers for Disease Control (CDC), in order to support novel coronavirus test results.
As a result, data from coronavirus clinical trials is now flowing in from its global network of healthcare organizations (HCOs).
Moreover, the company is collaborating with its network of 150 HCOs to connect pharmaceutical companies to sites that are open to receiving clinical trials and observational studies related to the pandemic.
“Accelerating research holds the key to stemming the tide of this insidious disease,” said Gadi Lachman, CEO of TriNetX. He added that, in order to achieve this goal, the company must provide researchers with the tools and data to understand the virus.
“To further that goal, we are rapidly engaging our industry and healthcare organization partners who are preparing to open clinical trials around supportive, curative, and preventative COVID-19 therapies and vaccines,” stated Lachman.
